



Astec LifeSciences Ltd.

Dated: 24th May, 2013

To,
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra, Mumbai-400051

Ref: "ASTEC"

Sub: Outcome of Board Meeting.

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on Friday 24th May, 2013 has:


- 1) Approved the Audited Financial Results (both Standalone & Consolidated) for the year ended 31st March, 2013.
- 2) Recommended a dividend of Seventy Five paise per share (i.e. 7.5% on the face value of Rs.10/- each) for the approval of the Shareholders at the ensuing Annual General Meeting.
- 3) Board has approved the appointment of M/s Shah & Kathariya, Chartered Accountants, Mumbai as Statutory Auditors of the Company for the Financial Year 2013-2014 in place of retiring Auditors M/s. P. M. Kathariya & Co., Chartered Accountants. The retiring Auditor expressed their inability to continue as Statutory Auditors of the Company due to their pre-occupations.

Please take the same on your records.

Thanking you,

Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED


Vikas R. Chomal

Company Secretary & Compliance Officer



Encl: as above



ISO 9001:2008



ISO 14001:2004



OHSAS 18001:2007

Head Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone: +91-22- 2261 8212/ 2261 8504
Fax : +91-22- 2261 8289
E-mail : ah@astecls.com
Website : www.astecls.com



ASTEC

Regd. Office : 7th Floor, Elite Square, 274, Perin Nariman Street, Fort, Mumbai - 400001.

ASTEC LIFESCIENCES LTD

Audited Financial Results for the Year Ended 31 March, 2013

PART I

STANDALONE (Rs. in Lacs except for data per share)

CONSOLIDATED (Rs. in Lacs except for data per share)

Sr. No	Particulars	Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012	31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012
1	Income from Operations	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
	a) Net Sales / Income from operations (Net of Excise Duty)	5,695.28	3,825.51	2,563.49	16,527.07	11,084.06	5,721.18	4,055.78	2,540.42	17,448.10	11,284.48
	b) Other Operating Income	1.11	8.39	32.89	38.68	74.01	1.11	9.26	17.72	25.36	32.58
	Total Income from Operations (net)	5,696.39	3,833.91	2,596.38	16,565.75	11,158.07	5,722.29	4,065.05	2,558.14	17,473.46	11,317.06
2	Expenses										
	a) Cost of materials consumed	4,023.18	2,585.19	2,101.90	11,802.29	8,479.21	4,028.66	2,738.56	1,934.81	11,969.84	8,923.94
	b) Purchase of stock in trade	-	-	-	-	696.99	-	-	-	-	696.99
	c) Changes in inventories of finished goods and WIP	360.66	136.55	(142.14)	312.42	(823.86)	285.28	98.69	19.76	312.41	(1,174.91)
	d) Employee benefits expenses	247.22	232.28	94.58	829.46	474.79	247.22	257.65	130.19	909.86	557.53
	e) Depreciation and amortisation expenses	316.06	314.99	224.24	1,173.21	847.54	326.50	326.23	225.49	1,187.42	863.79
	f) Other expenditure	252.07	211.27	106.59	559.51	441.73	301.35	281.62	136.96	1,354.68	540.41
	Total Expenses	5,199.19	3,480.28	2,385.17	14,676.89	10,116.39	5,189.01	3,702.75	2,447.21	15,734.21	10,407.74
3	Profit / (loss) from operations before other income, Finance Cost and Exceptional Items (1-2)	497.20	353.63	211.21	1,888.86	1,041.67	533.28	362.30	110.93	1,739.25	909.31
4	Other Income	12.35	28.03	7.00	(85.26)	27.88	12.35	28.03	7.01	105.72	28.73
5	Profit / (loss) from ordinary activities before finance cost and exceptional items (3+4)	509.56	381.65	218.21	1,803.60	1,069.55	545.64	390.32	117.94	1,844.97	938.04
6	Finance Costs	158.91	171.58	135.15	703.22	534.29	123.99	210.87	147.45	748.49	565.92
6A	Foreign Exchange Fluctuation (Profit) / Loss	(41.18)	142.40	61.78	130.88	176.83	(41.18)	142.40	61.77	130.87	176.83
7	Profit after finance costs but before Exceptional Items (5-6-6A)	391.83	67.68	21.28	969.50	358.43	462.83	37.06	(91.28)	965.61	195.29
8	Exceptional Items	73.24	0.08	10.64	94.92	14.11	73.24	0.08	10.64	94.93	14.11
9	Profit / (loss) from ordinary activities before tax (7-8)	318.60	67.60	10.64	874.57	344.32	389.60	36.98	(101.92)	870.69	181.18
10	Tax Expense (including deferred tax)	95.60	35.33	35.78	280.12	102.52	96.00	34.21	(14.64)	279.40	53.79
11	Net Profit Profit / (Loss) from ordinary activities after tax (9-10)	223.00	32.27	(25.14)	594.45	241.80	293.60	2.77	(87.28)	591.29	127.39
12	Extra ordinary Items										
13	Net Profit / (Loss) for the period (11 - 12)	223.00	32.27	(25.14)	594.45	241.80	293.60	2.77	(87.28)	591.29	127.39
14	Minority Interest	-	-	-	-	241.80	-	0.15	0.04	(4.97)	(9.17)
15	Net Profit / (Loss) after taxes, minority interest (13-14-15)	223.00	32.27	(25.14)	594.45	241.80	293.60	2.63	(87.32)	596.26	136.56
16	Paid-up equity share capital (Face Value Rs.10/-)	1,804.41	1,692.91	1,692.91	1,804.41	1,692.91	1,804.41	1,692.91	1,692.91	1,804.41	1,692.91
17	Reserves (excluding Revaluation Reserve)					8,147.35				8,728.97	8,023.59
18	Earnings per share - Basic	1.30	0.19	(0.15)	3.45	1.43	1.71	0.02	(0.52)	3.47	0.81
	Diluted	1.29	0.19	(0.15)	3.36	1.43	1.69		(0.52)	3.44	0.81



PART II		Quarter Ended				Year Ended	
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012	
A PARTICULARS OF SHAREHOLDING							
1	Public shareholding						
	- No of shares	7,772,150	7,497,150	-	7,772,150	7,497,150	
	- Percentage of shareholding	43.07%	44.29%	0.00%	43.07%	44.29%	
2	Promoters and promoter group shareholding						
	a) Pledged / Encumbered						
	- No of shares						
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group	0.00%	0.00%	0.00%	0.00%	0.00%	
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	
	b) Non-encumbered						
	- No of shares	10,271,980	9,431,980	9,431,980	10,271,980	9,431,980	
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group	100.00%	100.00%	100.00%	100.00%	100.00%	
	- Percentage of shares (as a % of the total share capital of the company)	56.93%	55.71%	55.71%	56.93%	55.71%	
B INVESTOR COMPLAINTS							
	Pending at the beginning of the quarter	Nil					
	Received during the quarter	1					
	Disposed of during the quarter	1					
	Remaining unresolved at the end of the quarter	Nil					
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on May 24 , 2013.						
2	The company has only one reportable segment i.e. Agrochemicals & Pharma Intermediates.						
3	Above Financial Results includes financials results of M/s Behnam Chemicals Pvt. Ltd. (65.63% subsidiary), Astec Europe SpA (50.10% subsidiary) and Astec CropCare Pvt Ltd (100% Subsidiary of Astec)						
4	The Board of Directors has recommended a dividend of 7.5% on the share capital of the company i.e 75 Paise per Share of Rs.10/- each. (Previous year 5% i.e 50 Paise Per Share)						
5	Figures of the previous period have been regrouped/rearranged, wherever necessary.						
6	Company has successfully commissioned two new projects for its contract customers during the year						
7	Company has made investments to upgrade EHS standards						
8	Company has obtained several new registrations during the year						
9	The figures of last Qtr ended 31.03.13 & 31.12.12 are the balancing figures in respect of the full financial year & the year to date figures upto third quarter.						
Key standalone financial information of the company is given below :-							
Particulars		Qtr Ended 31/03/2013	Qtr Ended 31/12/2012	Qtr Ended 31/03/2012	Year Ended 31/03/2013	Year ended 31/03/2012	
Net Sales / Income from operations (Net of Excise Duty)		5,695.28	3,825.51	2,563.49	16,527.07	11,084.06	
Other Operating Income		1.11	8.39	32.89	38.68	74.01	
Profit / (loss) from ordinary activities before tax		318.60	67.60	10.64	874.57	344.32	
Net Profit Profit / (loss) from ordinary activities after tax		223.00	33.39	(25.14)	594.45	241.80	
Earnings per share - Basic		1.30	0.20	(0.15)	3.45	1.43	
Earnings per share - Diluted		1.29	0.20	(0.15)	3.36	1.43	

For Astec Lifesciences Limited

(Ashok Vitthamath)

Chairman & Managing Director

Mumbai, May 24, 2013

